In a concerted effort to safeguard the inviolability of personal genetic information, a coalition of twenty-seven states, alongside the District of Columbia, has initiated legal proceedings against 23andMe, the consumer genomics purveyor, seeking injunctive relief against the prospective commodification of individual genetic data absent explicit, informed consent, a measure precipitated by a biotech firm's proposed acquisition of the financially beleaguered entity; Oregon Attorney General Dan Rayfield, in a formal communiqué, posited that the bio-informational corpus at stake—encompassing biological matrices, deoxyribonucleic acid sequences, phenotypic predispositions, and longitudinal medical dossiers—cannot be alienated without the unambiguous, prior authorization of each data principal, particularly given 23andMe's protracted struggle for economic viability since its initial public offering in 2021, culminating in substantial workforce reductions and Chapter 11 recourse, notwithstanding Regeneron Pharmaceuticals' declared commitment to upholding extant privacy protocols and the appointment of an independent ombudsman to scrutinize the sale's ramifications for consumer privacy rights.